2024-20081. Medical Devices; Gastroenterology-Urology Devices; Classification of the Hemodialyzer With Expanded Solute Removal Profile  

  • Table 1—Hemodialyzer With Expanded Solute Removal Profile Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Adverse tissue reaction Biocompatibility evaluation, Pyrogenicity testing, and Non-clinical performance testing.
    Infection or pyrogen reaction Labeling, Pyrogenicity testing, Sterilization validation, Non-clinical performance testing, and Shelf-life testing.
    Inadequate or incomplete treatment Non-clinical performance testing, Labeling, and Shelf-life testing.
    Clearance of essential blood substances or medications Non-clinical performance testing, Clinical performance testing, Labeling, and Shelf-life testing.
    Blood loss or blood cell destruction Non-clinical performance testing, Labeling, and Shelf-life testing.
    Blood leak into the dialysis fluid Non-clinical performance testing, Labeling, and Shelf-life testing.
    Air or particle embolism Non-clinical performance testing, Labeling, and Shelf-life testing.
    Fluid imbalance Non-clinical performance testing and Labeling.
    Acid-base imbalance Non-clinical performance testing and Labeling.

Document Information

Effective Date:
9/6/2024
Published:
09/06/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-20081
Dates:
This order is effective September 6, 2024. The classification was applicable on August 28, 2020.
Pages:
72715-72717 (3 pages)
Docket Numbers:
Docket No. FDA-2024-N-3972
Topics:
Medical devices
PDF File:
2024-20081.pdf
CFR: (1)
21 CFR 876